» Articles » PMID: 2843624

Acute and Chronic Opiate-regulation of Adenylate Cyclase in Brain: Specific Effects in Locus Coeruleus

Overview
Specialty Pharmacology
Date 1988 Sep 1
PMID 2843624
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

Acutely, morphine and D-ala2-D-leu-enkephalin (DADLE) inhibited adenylate cyclase in vitro in locus coeruleus (LC), dorsal raphe, frontal cortex and neostriatum and the inhibition by each agonist was blocked by the opiate-receptor antagonist naloxone. Although morphine was equally efficacious in the four brain regions examined (10-15% inhibition), DADLE inhibited cyclic AMP (cAMP) production to a greater extent in cortex and striatum (20-25% inhibition). Pertussis toxin treatment in vitro significantly reduced DADLE-inhibition of adenylate cyclase in all brain areas, indicating that this opiate response is mediated by a pertussis toxin-sensitive G-protein (i.e., Gi and/or Go). Chronic (in vivo) administration of morphine pellets for 5 days, treatment known to induce opiate tolerance and dependence, increased basal, GTP- and forskolin-stimulated adenylate cyclase in the LC, but not in the other three brain regions studied. DADLE was found to inhibit cAMP production in LC in vitro to the same extent in control and morphine-treated rats, suggesting a lack of opiate receptor tolerance. The morphine-induced increase in adenylate cyclase required chronic exposure to the opiate, as shorter treatment times, namely 2 hr and 1 day, failed to produce this effect. In fact, at 2 hr a small decrease in adenylate cyclase in the LC was observed that did not appear to be due to morphine being retained in the membrane fraction. Taken together, the findings of this study provide support for the view that changes in the cAMP system in the LC play a role in mediating acute opiate action as well as in underlying the development of opiate tolerance, dependence and/or withdrawal.

Citing Articles

A Balancing Act: Learning from the Past to Build a Future-Focused Opioid Strategy.

Gooding S, Whistler J Annu Rev Physiol. 2023; 86:1-25.

PMID: 38029388 PMC: 10987332. DOI: 10.1146/annurev-physiol-042022-015914.


Key differences in regulation of opioid receptors localized to presynaptic terminals compared to somas: Relevance for novel therapeutics.

Coutens B, Ingram S Neuropharmacology. 2022; 226:109408.

PMID: 36584882 PMC: 9898207. DOI: 10.1016/j.neuropharm.2022.109408.


The CUL3/neddylation inhibitor MLN4924 reduces ethanol-induced locomotor sensitization and inflammatory pain allodynia in mice.

Ding Z, Knipp G, van Rijn R, Chester J, Watts V Behav Brain Res. 2020; 399:113051.

PMID: 33279641 PMC: 7855618. DOI: 10.1016/j.bbr.2020.113051.


Genome-Wide Small Interfering RNA Screening Reveals a Role for Cullin3-Really Interesting New Gene Ligase Signaling in Heterologous Sensitization of Adenylyl Cyclase.

Ding Z, Ejendal K, Soto-Velasquez M, Hayes M, Santoro N, Larsen M J Pharmacol Exp Ther. 2019; 372(3):267-276.

PMID: 31857349 PMC: 7011112. DOI: 10.1124/jpet.119.261255.


Phosphorylation of unique C-terminal sites of the mu-opioid receptor variants 1B2 and 1C1 influences their Gs association following chronic morphine.

Chakrabarti S, Liu N, Gintzler A J Neurochem. 2019; 152(4):449-467.

PMID: 31479519 PMC: 7042086. DOI: 10.1111/jnc.14863.